Quote:

---

He's not selling for less than $50 IMO

---

I'm not sure $50 is the threshold (although I would not be disappointed with that) -- but I really can't imagine $10 would move the needle for NP or the other large stakeholders.

I remember in the March 5th call NP effectively stating that he was trying to quickly move as many indications forward as possible -- so that the molecule's intrinsic value would be fully priced-in a BO offer. And then he said that he would ultimately go along with whatever the shareholders decided in terms of the offer.

It's not really available in the 10Q, but I wonder what percentage of the authorized shares are either owned, or controlled, by individuals who are largely aligned with NP's opinion of the company's valuation. Personally, I would hate to see this company sold for pennies of what its worth.

Lastly, if a BO offer does come, I have a growing sense that it will not be from Gilead. From my limited understanding of historical interactions between CytoDyn and Gilead, and Gilead's recent acquisitions (or rumors of acquisitions), I sense they currently have no interest.

I suppose that could quickly change with positive cancer results, or NASH and GvHD. But if an offer does eventually appear, I'm guessing it comes from a BP that needs to refresh or fortify their IP, and in the process, wants to compete head-to-head with Gilead in the overlapping indications.